ERNA

NASDAQ Healthcare

Ernexa Therapeutics Inc. - Common Stock

Biotechnology

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

�� 市场数据

价格	$7.12
成交量	453,426
市值	8.30M
贝塔系数	2.510
RSI（14日）	47.0
200日均线	$18.60
50日均线	$7.97
52周最高	$71.50
52周最低	$3.18
市盈率	0.01
Forward P/E	-0.74
Price / Book	1.21